AbelaDrug200

Small molecule

AAbela Pharmaceuticals, Inc.

AbelaDrug200 is one of 14 small molecule programs targeting Head Injury. It is currently in development.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Head InjuryActive, not recruiting

Head InjuryPhase 1/Phase 2

Active, not recruiting

Competition

Competitive Landscape

15 competitors in Head Injury

#DrugCompanyPhaseTrials

Lipitor

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Approved

1 2

Epsom Salt

FFresenius Kabi Oncology Ltd.

Cyklokapron

2 4

Crestor

AstraZeneca

Phase 2

1 5

Human Serum Albumin

FFresenius

Phase 3

1 6

Osmitrol

BB. Braun Medical Inc.

Phase 2

1 7

Depakote

Teva

Preclinical

1 8

Oxycyte

TTenax Therapeutics, Inc.

Phase 2

1 9

Direct Anticoagulant

Bayer

Preclinical

1 10

Cortrosyn

Novartis

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Head Injury1 trial

Controlled Trial of ABELADRUG200 in Closed, Severe Head Injury

Unknown status·AAbela Pharmaceuticals, Inc.·Phase 1/2·NCT00810940·30 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for AbelaDrug200. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — AbelaDrug200 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for AbelaDrug200. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Abela Pharmaceuticals, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Company: AAbela Pharmaceuticals, Inc.

AbelaDrug200

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Head Injury1 trial

References

Drug Info

Quick Facts

Related News